Filing Flows › Journey Medical (DERM) › Q1 2026
Journey Medical (DERM) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Journey Medical (DERM) reported revenue of $16.0M for the first quarter 2026 (Q1 2026), +21% from a year earlier and -0.7% from the quarter before. Operating margin was -9.3%, net loss $2.2M (14.0% of revenue).
Journey Medical, Q1 2026: revenue $16.0M (+22% year over year), operating margin -9.3%, net loss $2.2M, operating cash flow $2.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $16.0M | -0.7% | +21% |
| Operating profit | −$1.5M | — | — |
| Net earnings | −$2.2M | — | — |
| Operating cash flow | $2.9M | — | — |
What changed
Revenue was $16.0M in Q1 2026, up 21% year over year and down 1% from the previous quarter. Emrosi was the largest line at 39% of revenue. Emrosi added $4.2M year over year (up 202%), 148% of the total change. Other / legacy declined 62%.
Operating costs exceeded revenue by $1.5M, an operating margin of -9.3%. Total costs grew 6% against revenue growth of 21%. The fastest-growing cost line was Cost of revenue (+30%). The quarter ended with a net loss of $2.2M, wider than the previous quarter's $1.2M loss.
Operating cash flow was $2.9M. Non-cash charges added back $1.0M of share-based compensation. Working capital and other items added $4.2M.
Questions
What was Journey Medical's revenue in the first quarter 2026?
Journey Medical (DERM) reported revenue of $16.0M for the first quarter 2026 (Q1 2026), +21% from a year earlier and -0.7% from the quarter before.
Was Journey Medical profitable in the first quarter 2026?
Operating loss was $1.5M (-9.3% of revenue) and net loss $2.2M.
Source: Journey Medical 10-Q on SEC EDGAR.